RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza. This approach aims to deliver immediate and sustained protection against severe viral disease, particularly for immunocompromised populations. The LAAbs provide protection independent of the patient's ability to mount a maximal response to seasonal vaccines.
Funding
Funding not disclosed
Founders
Product
Problem
Vulnerable populations face significant risks from viral infections, including severe disease and death. Current solutions may not provide immediate or long-lasting protection against both existing and emerging viral threats.
Solution
RQ Bio develops broad-spectrum monoclonal antibodies (mAbs) designed to offer immediate and sustained immunity against a wide range of viral infections. Their technology aims to protect individuals at high risk, providing a proactive defense against current and future viral threats. By focusing on broad-spectrum protection, RQ Bio seeks to address the limitations of narrow-spectrum antivirals and vaccines, particularly for those with compromised immune systems or limited access to healthcare. The mAbs are engineered to neutralize a diverse array of viral strains, reducing the likelihood of severe outcomes and improving overall health security.
Target Audience
The primary target audience includes vulnerable populations at high risk of severe disease or death from viral infections.
Features
- Broad-spectrum monoclonal antibodies targeting a wide range of viral infections.
- Designed for immediate and long-lasting immunity.
- Focus on protecting vulnerable populations at high risk of severe disease or death.
- Aims to provide protection against both current and emerging viral threats.